

# ARCH BIOPARTNERS INC.

## **Re: Material Change Report** **Form 51-102F3**

### **1. Name and Address of Company:**

Arch Biopartners Inc., (the “Company”)

174 Spadina Avenue Suite 502A  
Toronto, Ontario  
M5T 2C2.

### **Mailing:**

27 St. Clair Ave East  
P.O. Box 305  
Toronto, Ontario  
M4T 2M5

### **2. Date of Material Change:**

August 5, 2014

### **3. News Release:**

A news release was distributed via Canadian Marketwire in Toronto on August 5, 2014. A copy of the News release is attached as Schedule “A”.

### **4. Summary of Material Change**

The Company closed a private placement of Units.

### **5. Full Description of Material Change**

The Company announced the closing a private placement. The Company issued 625,500 Units at a price of \$0.28 per Unit, for gross total proceeds of \$175,140. Each Unit comprises of one common share and one common share purchase warrant. Each warrant allows the holder to purchase an additional common share at \$0.50 cents during the 24 month period following the close of the private placement. The proceeds will be used for the Company’s working capital and general corporate purposes. The common shares and any common shares issued from the exercise of the warrants will be subject to a hold period of 4 months from the closing date of August 5, 2014.

As a result of the closing of the private placement, the Company's total common shares outstanding increased to 50,975,179.

Management of the Company believes the material changes described herein will have a positive impact on the Company's cash position, business operations and prospects for future corporate activity.

**6. Reliance on subsection 7.1(2) or (3) of NI51-102**

Not applicable.

**7. Omitted Information**

No information has been omitted from this report on the basis that it is confidential information.

**8. Executive Officer**

For further information regarding this report, please contact Richard Muruvé, a Director and CEO of the Company, at 647-428-7031.

The foregoing accurately discloses the material changes referred to herein.

**DATED at Toronto, this 18<sup>th</sup> day of August, 2014.**

**SCHEDULE A  
PRESS RELEASE  
FOR IMMEDIATE DISTRIBUTION**

**ARCH BIOPARTNERS COMPLETES PRIVATE PLACEMENT**

**Toronto, ON – August 5, 2014 - Arch Biopartners Inc (“Arch” or the “Company”)(CSE-ACH and OTC: FOIFF)** announced today it has raised \$175,140 via a non-brokered private placement of 625,500 Units at a price of \$0.28 per Unit. Each Unit comprises of one common share and one common share purchase warrant. Each warrant allows the holder to purchase an additional common share at \$0.50 cents during the 24 month period following the close of the private placement. The proceeds will be used for the Company’s working capital and general corporate purposes. The common shares and any common shares issued from the exercise of the warrants will be subject to a hold period of 4 months from the closing date.

The Company now has 50,975,179 common shares outstanding.

**About Arch Biopartners**

Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies. The Company’s lead technology is in the area of targeting brain tumor initiating cells for the purpose of developing new imaging, diagnostic and therapeutic treatments for malignant glioma.

For more information on the Company, please consult the other public documents filed on SEDAR at [www.sedar.com](http://www.sedar.com).

The Company’s website address is: [www.archbiopartners.com](http://www.archbiopartners.com) .

*Forward-Looking Statements*

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.

**The CSE has not reviewed and does not accept responsibility for the adequacy of this release.**